Chinese Journal of Dermatology ›› 2026, Vol. 59 ›› Issue (10): 947-952.doi: 10.35541/cjd.20260312

• Original Articles • Previous Articles     Next Articles

Clinical application of the clinical pathway for neurosyphilis: a pilot study

Zheng Xiaoli1, Wu Minzhi2, Du Fangzhi1, Long Fuquan3, Zhou Zhe4, Yang Ligang5, Chen Wei6, Li Aili7, Jiang Faxing8, Jin Shouyue9, Gao Ying10, Zhao Jianbin11, Ren Xuqi12, Li Shishen13, Wang Yan14, Feng Suying15, Xie Bibo16, Zhang Ruili17, Wang Qianqiu18   

  1. 1Department of STD Clinical Management and Intervention, National Center for STD Control, Chinese Center for Disease Control and Prevention, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China; 2Department of Dermatology, the Fifth People's Hospital of Suzhou, Suzhou 215131, China; 3Department of Sexually Transmitted Diseases, Shanghai Skin Disease Hospital, Shanghai 200003, China; 4Department of Dermatology, Xi′an North Hospital, Xi′an 710032, China; 5Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou 510091, China; 6Department of Dermatology, the Second Hospital of Nanjing, Nanjing 210003, China; 7Department of Sexually Transmitted Diseases, Dalian Dermatosis Hospital, Dalian 116000, China; 8Department of Dermatology, Anhui Provincial Hospital, Hefei 234000, China; 9Department of Neurology, Zhongshan Hospital, Xiamen University, Xiamen 361000, China; 10Department of Dermatology, the Central Hospital of Wuhan, Wuhan 430014, China; 11Department of Dermatology, Xuzhou No.1 People′s Hospital, Xuzhou 221002, China; 12Department of Dermatology, Affiliated Hospital of Nantong University, Nantong 226007, China; 13Department of Sexually Transmitted Diseases, Dermatology Hospital of Guangxi Zhuang Autonomous Region, Nanning 530007, China; 14Department of Dermatology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China; 15Department of Sexually Transmitted Disease, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China; 16Department of Dermatology, Zhejiang Provincial Dermatology Hospital, Huzhou 313299, China; 17Department of Dermatology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China; 18STD Center Office, National Center for STD Control, Chinese Center for Disease Control and Prevention, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
    Zheng Xiaoli and Wu Minzhi contributed equally to the article
  • Received:2026-06-02 Revised:2026-09-02 Online:2026-10-15 Published:2026-10-07
  • Contact: Wang Qianqiu; Zhang Ruili; Du Fangzhi E-mail:wangqq@ncstdlc.org; reallyvictor@126.com; dufangzhi_090724@163.com
  • Supported by:
    CAMS Innovation Fund for Medical Sciences （2021-I2M-1-001）; Jiangsu Provincial Medical Key Laboratory, Jiangsu Province Capability Improvement Project through Science, Technology and Education （ZDXYS202204）; Jiangsu Provincial Double Innovation Doctor Program （JSSCBS20221929）

PDF

4

Abstract: 【Abstract】 Objective To evaluate the clinical application performance of the Clinical Pathway for Neurosyphilis（Trial Version）. Methods This was a prospective, multicenter, uncontrolled implementation study. From January 2025 to March 2026, the Clinical Pathway for Neurosyphilis（Trial Version） was piloted at 16 Chinese neurosyphilis clinical surveillance sentinel sites/member institutions of the Neurosyphilis Research Alliance, the China "Belt and Road" Dermatology Alliance. Data on the performance of the clinical pathway in patients with neurosyphilis were collected. Results During the study period, a total of 1 703 hospitalized patients with suspected neurosyphilis were screened, and 485 （28.48%） were diagnosed with neurosyphilis. Among the confirmed patients, asymptomatic neurosyphilis was the most common type （241/485, 49.69%）; among the patients with symptomatic neurosyphilis, general paresis （95/485, 19.59%） and tabes dorsalis （59/485, 12.16%） were the most common clinical forms. Of the 485 confirmed patients, 438 were enrolled in the clinical pathway, corresponding to an entry rate of 90.31%; the entry rates for tabes dorsalis （59/59） and meningeal neurosyphilis （17/17） reached 100%, whereas entry rates for asymptomatic neurosyphilis （212/241, 87.97%） and other types （7/8, 87.50%） were relatively low. Of the 438 enrolled patients, 430 completed the pathway, with a completion rate of 98.17%; the completion rates for tabes dorsalis （59/59） and other types （7/7） reached 100%, whereas those for general paresis （80/85, 94.12%） and meningeal neurosyphilis （16/17, 94.12%） were relatively low. The overall variation rate was 6.62% （29/438）, with the highest variation rate observed in other types of neurosyphilis （1/7, 14.29%）, followed by asymptomatic neurosyphilis （17/212, 8.02%）. Thirty-seven patients （8.45%） received multidisciplinary consultations, primarily by specialists in neurology and psychiatry for complex comorbidities. Conclusion The Clinical Pathway for Neurosyphilis（Trial Version）generally performed well and can be further promoted.

Key words: Neurosyphilis, Clinical pathway, Clinical application, Entry rate, Completion rate, Variation rate

share this article

0
    /   /   Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://www.pifukezazhi.com/EN/10.35541/cjd.20260312

         http://www.pifukezazhi.com/EN/Y2026/V59/I10/947